DNLI
Denali Therapeutics Inc.
$19.38
+$0.74(+3.97%)
49
Overall
60
Value
50
Tech
39
Quality
Market Cap
$2.44B
Volume
2.30M
52W Range
$12.58 - $23.77
Target Price
$34.57
Order:
Income Statement
| Metric | Trend | Chart | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||
| Total Revenue | $129.2M | $26.3M | $335.6M | $48.7M | $105.1M | $330.5M | -- | -- | ||
| Total Revenue | $129.2M | $26.7M | $335.7M | $48.7M | $108.5M | $330.5M | -- | -- | ||
| GROSS PROFIT | ||||||||||
| Gross Profit | $129.2M | $26.7M | $335.7M | $48.7M | $108.5M | $330.5M | -- | -- | ||
| OPERATING EXPENSES | ||||||||||
| Operating Expenses | $-175.5M | $239.9M | $272.9M | $344.4M | $449.2M | $527.2M | $501.9M | $555.3M | ||
| Research & Development | $143.2M | $193.4M | $212.6M | $265.4M | $358.7M | $423.9M | $396.4M | $418.8M | ||
| Research Expense | $143.2M | $193.4M | $212.6M | $265.4M | $358.7M | $423.9M | $396.4M | $418.8M | ||
| Selling, General & Administrative | $32.3M | $46.5M | $60.3M | $79.1M | $90.5M | $103.4M | $105.4M | $136.6M | ||
| General & Administrative Expenses | $32.3M | $46.5M | $60.3M | $79.1M | $90.5M | $103.4M | $105.4M | $136.6M | ||
| Salaries & Wages | $-18.8M | -- | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-7.4M | $8.0M | $8.5M | $8.6M | $10.4M | $16.7M | $7.8M | -- | ||
| Depreciation & Amortization | $-7.4M | $8.0M | $8.5M | $8.6M | -- | -- | -- | -- | ||
| Amortization | -- | -- | -- | -- | -- | -- | $1.2M | -- | ||
| Other Operating Expenses | $-1.5M | $-2.6M | $-3.0M | $-4.7M | -- | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||
| Operating income | $-46.4M | $-213.2M | $62.7M | $-295.8M | $-340.7M | $-196.7M | $-487.3M | $-555.3M | ||
| EBITDA | $-28.8M | $-190.0M | $71.2M | $-287.2M | $-315.6M | $-172.4M | $-463.4M | $-507.9M | ||
| NON-OPERATING ITEMS | ||||||||||
| Intinc | $10.1M | -- | -- | -- | -- | $51.5M | $64.6M | $42.9M | ||
| Net Non-Operating Interest Income/Expense | $10.1M | -- | -- | -- | $-14.8M | $51.5M | $64.6M | $42.9M | ||
| Gain on Sale of Securities | -- | $200.0K | $100.0K | -- | -- | -- | -- | -- | ||
| Other Income/Expense | -- | $-15.6M | $-9.3M | $-4.6M | $-18.2M | $-51.5M | -- | -- | ||
| Other Special Charges | -- | $15.6M | $9.3M | $4.6M | $18.2M | $51.5M | -- | -- | ||
| PRE-TAX INCOME | ||||||||||
| EBIT | $-36.2M | $-198.0M | $62.7M | $-295.8M | $-326.0M | $-145.2M | $-437.2M | $-512.4M | ||
| Pre-Tax Income | $-36.2M | $-198.0M | $72.0M | $-291.2M | $-326.0M | $-145.2M | $-437.2M | $-512.4M | ||
| INCOME TAX | ||||||||||
| Tax Provision | -- | $351.0K | $823.0K | $-575.0K | $21.0K | $30.0K | $68.0K | $102.0K | ||
| NET INCOME | ||||||||||
| Net Income | $-36.2M | $-197.6M | $71.1M | $-290.6M | $-326.0M | $-145.2M | $-422.8M | $-512.5M | ||
| Net Income (Continuing Operations) | $-36.2M | $-197.6M | $71.1M | $-290.6M | $-326.0M | $-145.2M | $-437.3M | $-512.5M | ||
| Net Income (Discontinued Operations) | $-36.2M | $-197.6M | $71.1M | $-290.6M | $-326.0M | $-145.2M | $-422.8M | $-512.5M | ||
| Net Income (Common Stockholders) | $-36.2M | $-198.3M | $71.1M | $-290.6M | $-326.0M | $-145.2M | $-422.8M | $-512.5M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | $-507.3M | ||
| TOTALS | ||||||||||
| Total Expenses | $-175.5M | $239.9M | $272.9M | $344.4M | $449.2M | $527.2M | $501.9M | $555.3M | ||
| SHARE & EPS DATA | ||||||||||
| Average Shares Outstanding | $92.6M | $95.6M | $109.0M | $121.5M | $125.5M | $137.4M | $164.5M | $172.6M | ||
| Average Shares Outstanding (Diluted) | $97.7M | -- | $112.7M | $121.5M | $125.5M | $137.4M | $164.5M | $172.6M | ||
| Shares Outstanding | $190.6M | $210.8M | $121.0M | $122.8M | $136.7M | $139.2M | $145.2M | $158.6M | ||
| Basic EPS | $0.82 | $-2.07 | $0.65 | $-2.39 | $-2.6 | $-1.06 | $-2.57 | $-2.97 | ||
| Basic EPS (Continuing Operations) | -- | $-2.07 | $0.65 | $-2.39 | $-2.6 | $-1.06 | $-2.57 | $-2.97 | ||
| Diluted EPS | $-0.39 | $-2.07 | $0.63 | $-2.39 | $-2.6 | $-1.06 | $-2.57 | $-2.97 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $0.63 | $-2.39 | $-2.6 | $-1.06 | $-2.57 | $-2.97 | ||
| OTHER METRICS | ||||||||||
| Gains Loss On Disposal Of Discontinued Operations | -- | -- | -- | -- | -- | -- | $14.5M | -- | ||
| Net Income Discontinuous Operations | -- | -- | -- | -- | -- | -- | $14.5M | -- | ||
| Other Gand A | $32.3M | $46.5M | $60.3M | $79.1M | $90.5M | $103.4M | $105.4M | $136.6M | ||
| Rent And Landing Fees | $32.3M | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | DNLI | $19.38 | +4.0% | 2.30M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Denali Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW